Reliable biomarkers to evaluate the efficacy of anlotinib have not been fully elucidated yet.[10] The CD31-labeled activated circulating endothelial cell is a potential indicator for predicting the efficiency of anlotinib in NSCLC, although it requires further validation.[11] CEA of the present patient seems to be an informative indicator of anlotinib because the change of serum CEA was to some extent parallel with the radiographic changes of the pulmonary lesions. Here, CEACAM5 is linked to non-small cell lung carcinoma.